SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

Current Rheumatology Reports

, 15:337

Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus

  • Daniel J. WallaceAffiliated withCedars-Sinai Medical Center, David Geffen School of Medicine at UCLA Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Belimumab has recently been approved, and several other types of biological therapy with different mechanisms of action are currently in phase II and III studies. This review puts these approaches in context, emphasizing mechanistic categories and clinical trial designs. Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed.

Keywords

Biologicals Targeted therapy Systemic lupus erythematosus SLE FDA Treatment Cutaneous lupus Belimumab Epratuzumab T cell inhibition